Detailed Narrative
Strong Q1 FY26 Performance Driven by Regulated Markets
Senores Pharmaceuticals reported a robust Q1 FY26, with consolidated revenue growing 72% YoY to INR 138 crores. This strong top-line performance translated into a 60% YoY increase in EBITDA to INR 34 crores and a 95% YoY surge in PAT to INR 21 crores. The regulated markets segment was a primary growth driver, contributing INR 90 crores with a 69% YoY and 40% QoQ growth. Despite a YoY EBITDA margin compression of 170 bps to 24.8%, the company saw a QoQ improvement of 360 bps, and remains confident in achieving 50% top-line and 100% PAT growth for FY26.
Product Portfolio Expansion and CDMO-CMO Traction
The company received 4 USFDA approvals in Q1 2026, bringing its total approved products to approximately 70, and commercially launched 2 new products, increasing its commercialized ANDA portfolio to 24. For FY26, 15-16 ANDA products are slated for launch, predominantly in the second half. The CDMO-CMO segment demonstrated steady traction, adding 5 new products in Q1 FY26 to reach a portfolio of 27 products, and contributed INR 28 crores in revenue for the quarter. Management expects CDMO-CMO revenue to reach INR 200 crores for FY26, supported by a USD 23 million order book with 12-18 months visibility.
Strategic Focus on Government Contracts and Backward Integration
A significant portion (60-70%) of the US business is derived from government contracts and controlled substances, which provides stable demand and predictable revenue streams due to long-term contracts and fixed pricing structures. This strategy helps insulate the company from price erosion. The newly commissioned API facility in Chhatral, with a capacity of 100-150 metric tons per year, is progressing as planned, with FDA approval anticipated in Q2 FY27. This backward integration is expected to bolster the supply chain and enhance margins.
Emerging Markets Profitability and Domestic Branded Generics Growth
Emerging markets revenue grew 32% YoY to INR 29 crores, though the EBITDA margin remained stagnant at 6%. Management aims to stabilize this margin at 15-17% annually, targeting double-digit profitability this year and mid-teens next year. The domestic branded generics business showed significant momentum, growing over 4x YoY to INR 8 crores in Q1 FY26. The company plans to achieve INR 50 crores in revenue from this segment and establish a Pan-India presence by the end of FY26.
Capacity Expansion and Capital Expenditure Plans
Senores is actively expanding its US manufacturing capacity from 1.2 billion units to almost 2 billion units. The third manufacturing line in the US is expected to be operational by Q3 FY26, with the fourth line following by the end of FY26. The total capital expenditure for FY26 is projected to be between INR 100-150 crores, funded through a mix of internal accruals, debt, and IPO proceeds. This expansion is crucial for supporting future growth and operational efficiency.
Positive Operating Cash Flow and Regulatory Insulation
The company achieved a positive operating cash flow of INR 11 crores in Q1 FY26, marking a significant improvement in its cash flow trajectory. Management expressed confidence in sustaining this positive trend. Regarding potential US tariffs, the company believes it is well-insulated, as its entire formulation manufacturing is done locally in the US, and API procurement from China and Europe constitutes only small quantities.